ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020
Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Incidence of Secondary Pancreatic Exocrine Insufficiency after Metabolic Bariatric Surgery: a Systematic Review and Meta-Analysis.Obesity surgery · 2026Pooled it
- European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.United European gastroenterology journal · 2022Guideline
- Article
- Characteristics, Complications, Comorbidities, and Other Manifestations of Inflammatory Bowel Disease: A 7-Year Tertiary Center Experience.Clinics and practice · 2026Article
- THE IMPACT OF OBESITY ON THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASE.Arquivos de gastroenterologia · 2026Observational
- High prevalence of fatigue in patients with inflammatory bowel disease: association with physical activity intensity and sedentary behavior.Frontiers in public health · 2026Article
- Global, regional, and national burden of inflammatory bowel disease in persons aged 60-89 years from 1992 to 2021.BMC gastroenterology · 2025Article
- Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.Nature reviews. Gastroenterology & hepatology · 2025Review
- Docosahexaenoic acid (DHA) alleviates inflammation and damage induced by experimental colitis.European journal of nutrition · 2024Article
- Frailty Screening is Associated with Hospitalization and Decline in Quality of Life and Functional Status in Older Patients with Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2024Article
- Inflammatory bowel disease in Korea: epidemiology and pathophysiology.The Korean journal of internal medicine · 2022Review
- Burden of obesity in gastrointestinal and liver diseases.United European gastroenterology journal · 2022Article
- MiR-1-3p and MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon.Journal of Crohn's & colitis · 2022Article
- Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?Biomedicines · 2022Review
- Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016.Inflammatory bowel diseases · 2022Article
- Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study.Frontiers in medicine · 2022Article
- Positioning biologics in the treatment of IBD: A practical guideCurrent research in pharmacology and drug discovery · 2022Review
- Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2021Article
- Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Article
Corrections and comments
- Commented on by
- Commented on byReply.2020
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The epidemiology of inflammatory bowel disease (IBD) is progressively evolving impacting the type of patients with IBD we will see in clinical practice. In this review, we discuss specific challenges and solutions in the management of (1) obese, (2) older and (3) obstetric (pregnant) patients with IBD. With the global obesity epidemic, almost 1 in 3 patients with IBD are obese. Obesity is associated with greater difficulty in achieving remission, higher risk of disease relapse and higher burden and costs of hospitalization in patients with IBD. Obese patients also have inferior response to biologic therapy related to altered pharmacokinetics and obesity-mediated chronic inflammation. Surgical management of obese patients with IBD is also challenging. Similar to obesity, the prevalence of IBD in older patients is rising and it is anticipated that almost one-third of patients with IBD will be older than 60 years within the next decade. Older patients present unique diagnostic and therapeutic dilemmas, and management of these individuals warrants careful consideration of the risks of disease-related versus treatment-related complications, non-IBD-related extra-intestinal complications (eg, cardiovascular disease, malignancy), in the context of individual values, preferences, functional status and comorbidities. With evolving therapeutics, medical management of IBD surrounding pregnancy continues to be challenging. Overall, the management of pregnant patients requires a pro-active, multidisciplinary approach, with an emphasis on optimal disease control not just during, but prior to pregnancy. This often involves continuation of highly effective therapies, of which the vast majority are safe during pregnancy and breastfeeding, resulting in a reduction of risk of adverse maternal fetal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.